Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Many statements broadly match the label (e.g., subcutaneous administration and key boxed-warning/precaution concepts like glucose monitoring, fluid retention, and injection-site lipoatrophy). However, several indications are incomplete or incorrect relative to the provided label (missing SGA indication; idiopathic short stature is described correctly but adult/ISS phrasing is partial), and multiple details about other brands and product sameness are not supported by the supplied label text. Overall alignment is moderate with material unsupported/incorrect elements.
Category Scores
Accurate Statements
Omnitrope is administered via subcutaneous injection.
DOSAGE AND ADMINISTRATION: “The weekly dose should be divided over 6 or 7 days of subcutaneous injections.”
Risks associated with growth hormone therapy can include elevated blood sugar levels.
WARNINGS AND PRECAUTIONS: “Treatment with somatropin may decrease insulin sensitivity… impaired glucose tolerance and overt diabetes mellitus… Therefore, glucose levels should be monitored periodically.”
Risks associated with growth hormone therapy can include fluid retention (edema).
WARNINGS AND PRECAUTIONS: “Fluid retention during somatropin replacement therapy in adults may frequently occur.”
Risks associated with growth hormone therapy can include, rarely, carpal tunnel syndrome.
Risks associated with growth hormone therapy can include development of antibodies to the hormone.
In children, growth hormone therapy may affect glucose metabolism and potentially increase the risk of developing diabetes.
WARNINGS AND PRECAUTIONS: “previously undiagnosed impaired glucose tolerance and overt diabetes mellitus may be unmasked, and new onset type 2 diabetes mellitus has been reported” and glucose monitoring guidance (5.4).
In adults, growth hormone therapy can lead to fluid retention and joint pain.
Fluid retention: “Fluid retention… in adults may frequently occur.” Joint pain is not explicitly supported by the supplied label text.
Healthcare providers determine the precise dosage.
DOSAGE AND ADMINISTRATION: “Therapy with OMNITROPE should be supervised by a physician…” (dose individualized is not explicitly supported, but physician supervision is).
The '15mg 1 5ml' designation refers to the amount of medication in a vial or pen, indicating a concentration and total quantity, not the prescribed daily dose.
DOSAGE FORMS AND STRENGTHS: provides concentration/amounts (e.g., “5 mg/1.5 mL” and “10 mg/1.5 mL”) but the exact interpretation of “15mg 1 5ml” is not supported because that specific designation is not shown in the provided label text.
Detailed regulatory information and clinical trial data for Omnitrope can be found on the websites of regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Pharmaceutical manufacturers provide comprehensive prescribing information.
Unsupported Statements
Somatropin (active ingredient in Omnitrope) is prescribed to treat growth failure associated with idiopathic short stature in children.
Label supports idiopathic short stature (ISS) indication, but the statement is missing the label’s definition elements (SDS ≤ -2.25, epiphyses not closed, and diagnostic evaluation excludes other causes).
Somatropin is prescribed to treat growth failure associated with Prader-Willi syndrome in children.
Label supports PWS indication, but provided claim omits that diagnosis should be confirmed by genetic testing and that PWS-related contraindications/warnings exist (label contains these specifics).
Somatropin is prescribed to treat growth failure associated with Turner syndrome in children.
Label supports Turner Syndrome indication, but statement omits the label’s caution about cardiovascular monitoring.
Somatropin is prescribed to treat growth hormone deficiency of unknown etiology or known organic causes in children.
Label excerpt supports pediatric growth failure due to inadequate endogenous GH secretion, but the specific phrasing “unknown etiology or known organic causes” is not present in the provided label text.
Omnitrope is used to treat growth failure in children and adults with growth hormone deficiency.
Label excerpt (provided) specifically states indications for children with inadequate endogenous GH secretion and other pediatric conditions, but does not provide an adult GH deficiency indication within the supplied label text (only physician supervision text mentions adult GHD).
Common side effects of Omnitrope can include injection site reactions such as pain, redness, or itching.
No adverse reaction details on injection site pain/redness/itching are included in the provided label excerpts (only lipoatrophy tissue atrophy is mentioned as a warning/precaution).
Common side effects of Omnitrope can include muscle or joint pain.
Joint pain is not explicitly stated in the provided label excerpts; only fluid retention is. Muscle pain/joint pain are therefore unsupported by supplied text.
Common side effects of Omnitrope can include headaches.
Headache is not explicitly stated in the provided label excerpts.
Risks associated with growth hormone therapy can include development of antibodies to the hormone.
Antibody development is not mentioned in the provided label excerpts.
Risks associated with growth hormone therapy can include, rarely, carpal tunnel syndrome.
Carpal tunnel syndrome is not mentioned in the provided label excerpts.
Somatropin is available under several brand names, including Genotropin, Humatrope, Norditropin, and Saizen.
Brand-name comparators are not mentioned in the provided label excerpts.
All somatropin products, regardless of brand name, contain the same active pharmaceutical ingredient.
The provided label excerpt does not state cross-brand equivalence or “same active” across other manufacturers.
The primary differences between somatropin products often lie in the formulation, delivery devices, and potentially patent and exclusivity status.
Product comparison details are not stated in the provided label excerpts.
Dosage for Omnitrope is highly individualized and depends on the patient's age, weight, medical condition, and response to treatment.
The provided label excerpt only states “weekly dose should be divided…” and physician supervision; it does not provide the individualized factors list.
Detailed regulatory information and clinical trial data for Omnitrope can be found on the websites of regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Not supported by the provided FDA label excerpts.
Pharmaceutical manufacturers provide comprehensive prescribing information.
Not supported by the provided FDA label excerpts.
Contradictions
Low
AI Statement
All somatropin products, regardless of brand name, contain the same active pharmaceutical ingredient.
Label Reference
No contradiction can be directly established from the provided label excerpts; however, it is unsupported rather than contradicted.
Important Omissions
FDA label-supported indications for OMNITROPE in the provided excerpts include: growth failure in children born small for gestational age (SGA) who fail to manifest catch-up growth by age 2 years, and ISS with specific criteria (height SDS ≤ -2.25, epiphyses not closed, diagnostic evaluation excluding other causes). The user claims did not include SGA indication and did not include ISS definition details.
Importance:
Moderate
PWS diagnosis should be confirmed by appropriate genetic testing (label statement included in Indications and Usage excerpt). The user claims did not mention genetic testing confirmation.
Importance:
Moderate
Injection-site tissue atrophy/lipoatrophy risk and advice to rotate injection sites is included in Warnings and Precautions (5.13). The user claims did not mention lipoatrophy or injection-site rotation.
Importance:
Moderate
Warnings include intracranial hypertension with instruction to stop treatment if papilledema observed, intracranial symptoms within 8 weeks; the user claims did not mention this monitoring/treatment interruption requirement.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Some claims align with label concepts (glucose monitoring, fluid retention, subcutaneous administration), but multiple other safety/side-effect claims (antibodies, carpal tunnel, headaches, injection-site pain/redness/itching, muscle/joint pain) are not supported by the provided label excerpts. Missing label-specific indication criteria (ISS definition; SGA indication) and PWS genetic testing confirmation could lead to inaccurate characterization of labeled use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several statements are not supported by the supplied FDA label excerpts (e.g., antibodies, carpal tunnel syndrome, specific “common side effects” like injection-site pain/redness/itching, headaches, muscle/joint pain) and some labeled indications/criteria are omitted or generalized (no SGA indication; ISS definition details and PWS genetic testing confirmation omitted).
Suggested Improvement
Restrict claims to the exact label-supported indications and warned events present in the provided sections. Add missing label elements (SGA catch-up by age 2 years; ISS criteria SDS ≤ -2.25 and epiphyses not closed with exclusion of other causes; PWS genetic testing confirmation). Replace unsupported side-effect/risk statements with label-supported ones from Sections 5 (warnings/precautions) and 6 (adverse reactions categories).